Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2022

Genmab — Juli 2022

Planlagt Fastgjort Låst Flyttet Genmab
808 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bibob
    wrote on sidst redigeret af
    #692

    https://www.onclive.com/view/teclistamab-approaches-eu-approval-for-relapsed-refractory-multiple-myeloma?utm_source=sfmc&utm_medium=email&utm_campaign=07252022_OncLive_SAN-22-OSD1317_MM CC_Sanofi_Sarclisa_GLOBAL&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==
    Teclistamab.

    1 Reply Last reply
    0
    • D Offline
      D Offline
      Doublo
      wrote on sidst redigeret af
      #693

      Godmorgen:-) mon ikke den "generøse" kursforhøjelse fra BMO er et forsøg på at holde kursen nede, sjovt at man kan bruge en kursforhøjelse til det.

      1 Reply Last reply
      0
      • R Offline
        R Offline
        Riis7
        wrote on sidst redigeret af
        #694

        Godmorgen, Mon ikke 2500-2600 er fair value på Genmab indtil der kommer nyt for pipeline eller bedre salg på dara 🙂 vi er lige steget fra 1875 til 2600:-) market er stadig meget nervøs med Putins magt over gas/olie . de har os stadig tabt en voldgiftsag på deres bedst sælgende produkt.

        1 Reply Last reply
        0
        • P Offline
          P Offline
          peter12
          wrote on sidst redigeret af
          #695

          Ny artikel om HexElect https://www.nature.com/articles/s41587-022-01384-1

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #696

            I wonder if we can deduce from that , that they are actively working on a CD52/CD20 combination

            1 Reply Last reply
            0
            • P Offline
              P Offline
              peter12
              wrote on sidst redigeret af
              #697

              They
              mention CLL several times in the article

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #698

                would be nice if we could see some interest in the Hexelect platform with a deal at some point... we are also still waiting for BionTech to say anything about the HexaBody product they are probably working on...

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #699

                  Btw, another Nature article this month- Changing the face of thyroid eye disease https://www.nature.com/articles/s41433-022-02186-0

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #700

                    Just a moment...

                    favicon

                    (firstwordpharma.com)

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #701

                      Maybe a competitor for Horizon at a later stage in TED

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #702

                        Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations https://www.prnewswire.com/news-releases/janssen-announces-new-data-supporting-safety-and-efficacy-of-rybrevant-and-lazertinib-combination-for-patients-with-non-small-cell-lung-cancer-and-egfr-mutations-301593280.html

                        1 Reply Last reply
                        0
                        • D Offline
                          D Offline
                          deleted-user
                          wrote on sidst redigeret af
                          #703

                          Hvad hjælper det JnJ sender en PR kl. 15.29, når E L har breaket 14:53.....

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #704

                            haha really? maybe they want us to proof-read it first 😉

                            1 Reply Last reply
                            0
                            • D Offline
                              D Offline
                              deleted-user
                              wrote on sidst redigeret af
                              #705

                              Haha. I would like to subscribe E L when its possible

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #706

                                joking aside, it is important data on the road to approval outside of
                                the EGFR Exon 20 patients

                                1 Reply Last reply
                                0
                                • D Offline
                                  D Offline
                                  deleted-user
                                  wrote on sidst redigeret af
                                  #707

                                  Do you calculate NAV for Amivantamab these days?

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    ProinvestorNEWS
                                    wrote on sidst redigeret af
                                    #708

                                    USA/åbning: Walmart falder til bunds i rødt marked efter nedjustering
                                    https://www.proinvestor.com/investornyt/855566/usa-abning-walmart-falder-til-bunds-i-rodt-marked-efter-nedjustering

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      bikube
                                      wrote on sidst redigeret af
                                      #709

                                      Og $ stiger nu 7,35.

                                      1 Reply Last reply
                                      0
                                      • D Offline
                                        D Offline
                                        deleted-user
                                        wrote on sidst redigeret af
                                        #710

                                        Tillykke til Uttrup. Endnu en dansk etapesejr 🙂

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #711

                                          JNJ recently repeated they expect peak sales over $5bn LLi, at 8-10% royalty. Further approval is key ofcourse, and i am not sure how far they could get there, but it could be bigger as Kesimpta

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper